Treatment and management of myelofibrosis in the era of JAK inhibitors
Clodagh Keohane, Deepti H Radia, Claire N HarrisonDepartment of Haematology, Guy's and St Thomas' NHS Foundation Trust, London, UKAbstract: Myelofibrosis (MF) can present as a primary disorder or evolve from polycythemia vera (PV) or essential thrombocythemia (ET) to post-PV MF or po...
Guardado en:
Autores principales: | Keohane C, Radia DH, Harrison CN |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4f49a0ed1ad64993aad5401da2392057 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
por: Keohane C, et al.
Publicado: (2013) -
Evaluating the Safety, Efficacy, and Therapeutic Potential of Momelotinib in the Treatment of Intermediate/High-Risk Myelofibrosis: Evidence to Date
por: Bassiony S, et al.
Publicado: (2020) -
JAK2 V617F genotype is a strong determinant of blast transformation in primary myelofibrosis.
por: Giovanni Barosi, et al.
Publicado: (2013) -
Ruxolitinib as an emerging treatment in myelofibrosis
por: Emanuel RM, et al.
Publicado: (2013) -
Hereditary hemochromatosis and JAK2‐positive polycythemia vera
por: Ahmed Radwan, et al.
Publicado: (2021)